MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Protalix BioTherapeutics Company Profile (NYSE:PLX)

Consensus Ratings for Protalix BioTherapeutics (NYSE:PLX) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.80 (131.71% upside)

Analysts' Ratings History for Protalix BioTherapeutics (NYSE:PLX)
Show:
DateFirmActionRatingPrice TargetActions
4/23/2015Jefferies GroupInitiated CoverageHold -> Buy$2.00 -> $2.60View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2014R. F. LaffertyLower Price TargetBuy$8.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2014Jefferies GroupReiterated RatingHold$4.25 -> $3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2014JPMorgan Chase & Co.Lower Price TargetOverweight$8.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2014Jefferies GroupReiterated RatingHold$5.50 -> $4.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/24/2014R. F. LaffertyInitiated CoverageBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/14/2014Jefferies GroupBoost Price Target$5.00 -> $5.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/21/2013JPMorgan Chase & Co.Initiated CoverageOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/2/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha